Our website uses its own and third parties cookies for a high level of user-friendliness. If you continue to browse and  use this website we will assume that you agree with the policies.

R&D

Aptalung. Diagnosis of lung cancer using aptamer technology. Applications in circulating tumor cells (CTCs) and in aphystochemistry

The Tas1R3 receptor (taste receptor type 1 member 3) is a membrane protein that belongs to the family of G protein-associated receptors. Recent studies have identified the expression of this receptor in lung circulating tumor cells, and there is evidence to indicate that Tas1R3 expression levels can be very useful as a biomarker in non-small cell lung cancer (NSCLC), providing relevant information about the stage, the prognosis and the choice of treatment.

Through the AptaLung project, applications for Tas1R3 receptor as a diagnostic biomarker will be developed. For this purpose, two products that improve the management of patients with NSCLC are intended to be carried out in clinical practice:

i. development and validation of a diagnostic system based on the ELONA technique (Enzyme Linked Oligonucleotide Assay) capable of detecting circulating tumor cells (CTCs) in blood through its Tas1R3 membrane receptor

ii. Use of aptamers in histochemistry for the detection of the marker in samples of tumor tissue obtained by biopsy.

This project has been funded by the “Ministerio de Ciencia, Innovación y Universidades” within the RETOS-COLLABORATION Subprogram, Call 2017. The project is co-funded by the European Union with the aim of promoting technological development, innovation and quality research.

The AptaLung consortium is: Aptus Biotech (project leader), Atrys Health, the Ramón y Cajal Research Center for Health Research (IRYCIS), the Ramón Domínguez Foundation for Biosanitary R+D+i (FRD) and Research Foundation of the Hospital General Universitario de Valencia (FIHGUV)

ID: RTC-2017-6597-1

2018-2021